Merck Sharp + Dohme Corp.

Lycera Corporation

Wesley B Trotter

Neville J Anthony

Mark T Bilodeau

Thomas Daniel Aicher

Kun Liu

Kenneth Jay Barr

James C Barrow

Peter J Manley

Nunzio Sciammetta

Brian M Andresen

Catherine M White

Matthew H Daniels

Scott E Wolkenberg

Blair T Lapointe

Zhijian Zhao

Michael Steven Poslusney

Chad A VanHuis

James J Mulhearn

Kausik K Nanda

John K MacLean

Vladimir Simov

Corey E Bienstock

Scott T Harrison

Yuan Liu

Nathan R Kett

Amy Zartman

Jeffrey W Schubert

The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT. 

2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease

The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.

Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders

Growing community of inventors

Boston, MA, United States of America

Wesley B Trotter